

## Original Research Article

### **Lack of association between endothelial nitric oxide synthase gene polymorphisms and coronary artery disease among Egyptian population.**

#### **Abstract**

Controversial results regarding the association of e NOS gene polymorphisms with CAD have been reported up to now, there has been conflicting data regarding the association between two clinically relevant polymorphisms {T-786C) in the promoter region and intron 4 variable number of 27-bp tandem repeats (VNTR) of the eNOS gene and **coronary artery disease** (CAD). The present study was undertaken to investigate association of these two eNOS gene polymorphisms with susceptibility to CAD in Egyptian population. A total of 80 patients with CAD and 40 healthy controls were included in this study. CAD patients were divided according to their body mass index (BMI) limits into 2 main groups: normal weigh group (BMI: 18.5–24.9, n=40) and abnormal weight group (BMI $\geq$ 25, n= 40), the last group was further sub-divided into overweight group (BMI: 25.0–29.9, n= 20) and obese group (BMI $\geq$  30, n= 20).

The T-786C and intron 4 VNTR polymorphisms were analyzed by polymerase chain reaction (PCR) using specific primers. The T-786C polymorphism frequencies for T/T, T/C and C/C genotypes were 27.5%, 28.75%, 43.75% respectively in the CAD patients, and 35%, 37.5%, 27.5% in the control subjects, while allele frequencies for C, T were 58.12%, 41.87% in the CAD patients and 46.25%, 53.75%, in the control group. No significant differences were observed in genotype frequencies between CAD patient group when compared to control group, or between them according to allele frequency. Also, there was no significant differences in the genotype distribution and allele frequencies of T786-C polymorphism among the overweight and obese cases compared to normal weight subjects. The genotype frequencies for eNOS b/b, a/b, a/a were 45%,

50% and 5% in the CAD patients, and 35%, 65% and 0% in the control subjects, with no significant difference between the two groups. Also, there were no significant difference in the allele frequencies between the CAD patients (a: b = 30%:70%), and controls (a: b = 32.5%:67.5%) as well as in the distribution of genotype and alleles frequencies of intron 4 VNTR of eNOS gene when overweight and obese patient groups were compared with the normal weight patient group. Thus the present study suggested that the two eNOS gene polymorphisms (the eNOS T-786C and intron 4 VNTR polymorphisms) were unlikely to be major genetic susceptibility factors for CAD in the Egyptian population even after classification of the CAD patients according to their BMI. Further studies with larger sample size are required to be done to confirm these findings.

Keywords: CAD, eNOS, VNTR.

## Introduction

Myocardium (the muscle tissue that forms the wall of the heart) as any muscle tissue, requires oxygen to operate. This is supplied by the coronary arteries surrounding the heart. Over time a stenosis, i.e. a partial or complete occlusion, may develop in one or more of the coronary arteries due to various causes. A patient with stenosis in one or more arteries is said to have coronary artery disease (CAD) (Termeer et al., 2007). Like other common chronic diseases, CAD has a complex etiology that is postulated to involve both genetic and environmental factors (Weng et al., 2005). Coronary atherosclerosis, a prerequisite for the development of CAD, results from a defective endothelial function, which is attributed mainly to an altered production of NO, a vasodilator and atheroprotective molecule (Davignon and Ganz, 2004 and Özçetin et al., 2015). NO is one of the most versatile molecules and plays an important role in almost every biological system (Yoon et al., 2005 and Ben Ali et al., 2015). It can inhibit the adhesion,

54 aggregation and recruitment of platelets; vascular smooth muscle cells migration and  
 55 growth, also regulates some vessel-platelet interactions and limits the oxidation of  
 56 atherogenic low density lipoproteins cholesterol (LDL-C) **(Syed et al., 2010)**. Therefore,  
 57 the reduced bioavailability of NO is common to CAD, and defects in NO production and  
 58 function correlate well with the incidence of CAD **(Kim et al., 2007 and Abolhalaj et al.,**  
 59 **2013)**.

60 NO is synthesized from l-arginine catalyzed by nitric oxide synthase (NOS)**(Syed et**  
 61 **al., 2010)**. There are at least three isoenzymes of NOS: constitutive neuronal NOS (nNOS  
 62 or NOS-1), inducible NOS (iNOS or NOS-2), and constitutive endothelial NOS (eNOS or  
 63 NOS-3), which constitute a “gene family”, located on different chromosomes and  
 64 expressed in different cell lines **(Syed et al., 2010 and yang et al., 2014 )** Human eNOS  
 65 is located on chromosome 7q35 to 36 with a total size of 21 kb and encoded by a 26 exon  
 66 gene**(Syed et al., 2010)**. Because eNOS availability is regulated at transcriptional and  
 67 posttranscriptional levels and owing to its role in the production of NO, eNOS gene is  
 68 considered to be a potential candidate for CAD **(Searles, 2006)**.The eNOS gene presents  
 69 some polymorphisms that have been previously associated with angiographically  
 70 assessed CAD **(Casas et al., 2004)**.

71 Among several polymorphisms in eNOS gene, a single nucleotide polymorphism (SNP),  
 72 T-786C, was identified in the 5 flanking region of the eNOS gene involving a  
 73 substitution of thymine (T) to cytosine (C) at a locus 786 base pairs upstream  
 74 **(Nakayama et al., 1999)**. It is associated with reduction in the promoter efficiency and  
 75 the level of expressed enzyme leading to increased CAD risk **(Rios et al., 2005)**.Variable  
 76 number of tandem repeat (VNTR) polymorphism located in intron 4 of eNOS (eNOS4b/a  
 77 polymorphism) were also known to be associated with excess of risk of CAD **(Stangl et**  
 78 **al., 2000)**.

79 Numerous epidemiological studies evaluated the eNOS polymorphisms in patients with  
80 CAD, but the results are often conflicting **(Kim et al., 2007)**. Ethnic background is  
81 known to influence polymorphism frequencies and their effects on the disease  
82 **(Domingos et al., 2007)**.

83 The present study was there for undertaken to investigate the possible association  
84 between CAD and e NOS gene polymorphisms in Egyptian population. To the best of our  
85 knowledge, the current investigation is the first to evaluate such association in the  
86 Egyptian population

## 87 **Subjects and Methods**

### 88 **1. Subjects:**

89  
90 This study included 80 patients with coronary artery disease (CAD) (mean age:  $47.86 \pm$   
91  $0.34$  year, male / female: 43/37) and 40 healthy controls (mean age:  $46.15 \pm 0.56$  year, male /  
92 female: 13/27). Subjects diagnosed with stenosis 50% or more by coronary angiography in  
93 any of the coronary arteries or their branches were classified as CAD patients. This  
94 classification was defined according to the world health organization (WHO)  
95 recommendations (Low et al., 2009). BMI was determined by dividing the subject's mass by  
96 the square height, typically expressed in metric units.  $BMI = \text{kilograms} / \text{meters}^2$  (WHO,  
97 2000). CAD patients were recruited from health insurance and private polyclinics  
98 (Mansoura), as well as, Naser institute, and Cardiology National institute, Cairo, Egypt.  
99 Control subjects were proven to have no history of cardiac disease, diabetes, hypertension  
100 and they were normal weight individuals. Subjects who had smoking habits were excluded  
101 from the study. All patients and normal subjects gave **their informed consent to**  
102 **participate in this study.**

104 **Methods**

105 **2.1. Clinical investigation**

106 For all participants, echocardiography (Echo) and electrocardiography (ECG) were  
 107 performed at rest and/or stress in order to define the presence, distribution, and functional  
 108 status of CAD. Segmental Wall Motion Abnormalities (SWMA) has been used to define  
 109 myocardial ischemia, detect coronary artery perfusion impairment, and assess cardiac  
 110 function. Coronary angiography was performed in CAD patients for the assessment of the  
 111 extent and severity of CAD (**Christus et al., 2011**).

112  
 113 **2.2. Samples collection:**

114 Venous blood samples were collected from each examined subject after overnight  
 115 fasting in polyethylene tubes containing 0.1% ethylene diaminetetracetic acid (EDTA)  
 116 solution as an anticoagulant for DNA extraction.

117  
 118 **2.3. Molecular investigations:**

119 **2.3.1. DNA extraction:**

120 Genomic DNA was extracted from samples of whole blood by the the Generation DNA  
 121 Purification Capture Column Kit (Gentra systems, USA).

122  
 123 **2.3.2. Genotyping:**

124 ***Detection of  $T^{786 \rightarrow C}$  polymorphism in the 5'- flanking region of the e NOS gene***  
 125 ***(Shampa et al., 2006.).***

126 The presence of the T→C conversion at nucleotide position 786 in the 5- flanking  
 127 region of the eNOS gene was determined by using (Amplification Refractory Mutation  
 128 system) ARMS “PCR” amplification. For genotyping of T-786C, a newly developed allele-  
 129 specific PCR was used. The oligonucleotide primers used in the reaction are listed in figure  
 130 (1). Amplification was performed in a total volume of 25 µl containing 5 µl genomic

DNA, 1 µl 2684T and 1 µl 2684C primers, 0.5 µl T0 and 0.5 µl C0 primers, 12 µl 2X Taq complete master mix (Fermentase) and 5 µl PCR grade H<sub>2</sub>O. After 1 cycle initial denaturation at 96°C for 5 minutes, amplification was achieved by 35 cycles at 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 20 seconds, then final extension was done at 72°C for 5 minutes. The products of the PCR process were separated by electrophoresis on a 3% agarose gel and visualized with UV transilluminator, PCR generated T and C alleles at 176-bp and 250-bp respectively; the gel then be photographed with a digital camera (Fig. A).

***Detection of 27-bp repeat polymorphism in intron 4 of the e NOS gene (Qi et al., 2006)***

PCR amplification was used for genotyping of the 27-bp repeat polymorphism in intron 4 VNTR of the e NOS gene with the primers 5'- GCC CTATGG TAG TGC CTT -3' (forward) and 5'-CTC TTAGTG CTG TGG TCA C -3' (reverse). A 25 µl volume was used for each PCR reaction. We added 1 µl of each primer, together with 5 µl genomic DNA, 12 µl 2X Taq complete master mix, and 6 µl PCR grade H<sub>2</sub>O. Each reaction mixture was heated for 1 cycle at 94°C for 5 min for initialization, followed by 40 cycles of 94°C for 30 sec, 68°C for 30 sec and 72°C for 30 sec, and a final extension of 72°C for 8 min. The PCR products were separated by electrophoresis on a 3% agarose gel. The alleles 4b and 4a produced bands of 418 bp and 391 bp respectively; the 418 bp band indicated five repeats of the 27-bp (b allele), and a 391 bp band indicated four repeats (a allele) (Fig. B).




**Figure 1. Shows the primers used in the reaction and the expected PCR products.**

### Statistical analysis:

Data were statistically analyzed using SPSS statistical computer package version 10 software (SPSS 10, 1999). Quantitative variables were expressed as mean  $\pm$  SE, while the qualitative variables were presented as numbers and percentages. Comparison of qualitative data was done using chi-square test ( $\chi^2$ ). Quantitative data were compared using Independent- Samples T test or One Way ANOVA test. Statistical significance was set at  $p \leq 0.05$ .

### Results:

The clinical characteristics of the study subjects are shown in (Table 1a). CAD patients presented elevated values of systolic and diastolic blood pressure (SBP & DBP) and higher prevalence of traditional risk factors for CAD, including male gender, diabetes and BMI. Significant increases in these parameters was showed in obese and overweight patient groups when compared with the normal weight group. However, these changes together seemed to be more drastic in the obese patients

comparing with patients with normal weight profile(Table 1b). Also the prevalence of female gender in the obese group seemed to be significantly higher.

### **Endothelial nitric oxide synthase (e NOS) gene polymorphisms:**

Distribution of genotype and allele frequency of T786-C and intron 4 VNTR polymorphisms among the CAD patients and controls are shown in Table 2(a) and (b). Table 2 (a) showed that the genotype distribution of T786-C polymorphism in CAD patients and controls were 43.75% vs. 27.5% (CC), 28.75% vs. 37.5% (CT) and 27.5% vs. 35% (TT), respectively, and was found to be statistically non-significant ( $p = 0.23$ ). Allele frequencies of T786-C polymorphism in CAD patients and controls were 58.12% vs. 46.25% (C allele) and 41.87% vs. 53.75% (T allele), respectively, (C allele) tend to be higher but non-significant in patients than controls ( $p = 0.21$ ). Table 2 (b) showed that there was no significant difference in the genotype distribution and allele frequencies of T786-C polymorphism among the overweight cases compared to normal weight subjects(table .2b) CC, TC and TT genotypes (45% vs. 40%, 25% vs. 32.5% and 30% vs. 27.5%,  $p = 0.23$ , respectively). On the other hand, the frequencies of C and T alleles was slightly but non significantly differ between the two groups (57.5% vs. 56.25% and 42.5% vs. 43.75%,  $p = 0.12$ , respectively).Also, there was no significant differences in the genotype distribution of the T-786C polymorphism in the obese group compared to normal weight group CC, TC and TT genotypes (50% vs. 40%, 25% vs. 32.5% and 25% vs. 27.5%,  $p = 0.24$ , respectively).While, the comparison of the frequencies of C and T alleles between these groups revealed no significant difference (62.5% vs. 56.25% and 37.5% vs. 43.75%,  $p = 0.18$ , respectively).

Table 3(a) showed that the genotype distribution of eNOS intron 4 VNTR polymorphism in CAD patients and controls was 5% vs. 0% (aa), 50% vs. 65% (ab) and 45% vs. 35% (bb), respectively, and was found to be non-significant ( $p = 0.15$ ). Allele frequencies of intron 4 VNTR polymorphism in CAD patients and controls were 30% vs. 32.5% (a allele) and 70% vs. 67.5% (b allele), respectively ( $p = 0.12$ ). In table 3(b), there were no significant differences observed in the distribution of genotype and alleles frequencies of the intron 4 VNTR polymorphism when overweight patient group were compared with normal weight patient group, the genotype distribution was 10% vs. 2.5% (aa), 45% vs. 55% (ab) and 45% vs. 42.5% (bb), respectively ( $p = 0.28$ ). Allele frequencies of intron 4 VNTR polymorphism in overweight and normal weight patients were 32.5% vs. 28.75% (a allele) and 67.5% vs. 71.25% (b allele), respectively ( $p = 0.18$ ). In addition, no differences were found when obese group were compared with normal weight patient group according to genotype or allele frequency. The genotype distribution was 5% vs. 2.5% (aa), 45% vs. 55% (ab) and 50% vs. 42.5% (bb), respectively ( $P = 0.43$ ). Allele frequencies of this polymorphism in obese and normal weight patients were 27.5% vs. 28.75% (a allele) and 72.5% vs. 71.25% (b allele), respectively ( $p = 0.23$ ).

In table 3(b), there were no significant differences observed in the distribution of genotype and alleles frequencies of the intron 4 VNTR polymorphism when overweight patient group were compared with normal weight patient group, the genotype distribution was 10% vs. 2.5% (aa), 45% vs. 55% (ab) and 45% vs. 42.5% (bb), respectively ( $p = 0.28$ ). Allele frequencies of intron 4 VNTR polymorphism in overweight and normal weight patients were 32.5% vs. 28.75% (a allele) and 67.5% vs. 71.25% (b allele), respectively ( $p = 0.18$ ). In addition, no differences were found when obese group were compared with normal weight patient group according to genotype or allele frequency. The genotype distribution was 5% vs. 2.5% (aa), 45% vs. 55% (ab) and 50% vs. 42.5% (bb), respectively ( $P = 0.43$ ). Allele frequencies of this

polymorphism in obese and normal weight patients were 27.5% vs.28.75% (a allele) and 72.5% vs. 71.25% (b allele), respectively (p =0.23).

**Table 1(a). Clinical characteristics of the study subjects.**

230  
231

|                        | <b>Control<br/>(n=40)</b> | <b>CAD<br/>(n=80)</b> | <b>P value</b> |
|------------------------|---------------------------|-----------------------|----------------|
| <b>Age , Years</b>     | 46.15± 0.56               | 47.86± 0.34           | 0.33           |
| <b>Gender</b>          | <b>Male, n (%)</b>        | <b>13(32.5%)</b>      | 0.02           |
|                        | <b>Female, n (%)</b>      | <b>27(67.5%)</b>      |                |
| <b>BMI(Kg/m2)</b>      | 23.57± 0.36               | 27.39± 0.54           | 0.00           |
| <b>SBP(mm/Hg)</b>      | 120.88±1.06               | 133.25 ±1.45          | 0.00           |
| <b>DBP(mm/Hg)</b>      | 76.00±1.05                | 86.19±0.94            | 0.03           |
| <b>Diabetic, n (%)</b> | <b>0(0%)</b>              | <b>27(33.75%)</b>     | 0.00           |

Data are presented as mean± SEM. n: number of cases, (%): percentage of cases.

CAD: Coronary artery Disease; BMI: Body mass index, SBP= Systolic blood pressure, DBP=Diastolic blood pressure. p≤0.05 (significant)

235

**Table 1 (b).Clinical characteristics of CAD patients after classification according to BMI.**

|                        | <b>CAD<br/>(N=80)</b>           |                               |                         | <b>P1<br/>value</b> | <b>P2<br/>value</b> |
|------------------------|---------------------------------|-------------------------------|-------------------------|---------------------|---------------------|
|                        | <b>Normal weight<br/>(N=40)</b> | <b>Over weight<br/>(N=20)</b> | <b>Obese<br/>(N=20)</b> |                     |                     |
| <b>Age , Years</b>     | 47.75± 0.53                     | 47.60± 0.65                   | 48.35± 0.54             | 0.99                | 0.22                |
| <b>Gender</b>          | <b>Male, n (%)</b>              | <b>23(42.5%)</b>              | <b>16(80%)</b>          | 0.07                | 0.00                |
|                        | <b>Female, n (%)</b>            | <b>17(42.5%)</b>              | <b>4(20%)</b>           |                     |                     |
| <b>BMI(Kg/m2)</b>      | 23.92± 0.39                     | 27.76± 0.50                   | 33.97± 0.80             | 0.03                | 0.04                |
| <b>SBP(mm/Hg)</b>      | 131.50± 1.70                    | 133.00± 3.37                  | 137.00± 3.27            | 0.03                | 0.03                |
| <b>DBP(mm/Hg)</b>      | 79.50± 0.62                     | 91.25± 1.53                   | 94.50± 1.08             | 0.03                | 0.00                |
| <b>Diabetic, n (%)</b> | <b>11(27.5%)</b>                | <b>8(40%)</b>                 | <b>8(40%)</b>           | 0.24                | 0.24                |

Data are presented as mean± SEM. N: number of cases, (%): percentage of cases.

CAD: Coronary artery Disease; BMI: Body mass index, SBP= Systolic blood pressure, DBP=Diastolic blood pressure.p≤0.05 (significant).P1=If comparing overweight patients with normal weight patients. P2=If comparing obese patients with normal weight patients.

**Table 2(a). Genotype distribution and allele frequencies of T-786C polymorphism of the eNOS gene in the study subjects**

| Genotype        |                 | Control<br>(n=40) | CAD<br>(n=80) | P value |
|-----------------|-----------------|-------------------|---------------|---------|
| <i>Genotype</i> | CC, n (%)       | 11(27.5%)         | 35(43.75%)    | 0.23    |
|                 | TC, n (%)       | 15(37.5%)         | 23(28.75%)    |         |
|                 | TT, n (%)       | 14(35%)           | 22(27.5%)     |         |
| <i>Allele</i>   | C allele, n (%) | 37(46.25%)        | 93(58.12%)    | 0.21    |
|                 | T allele, n (%) | 43(53.75%)        | 67(41.87%)    |         |

Data are presented as number and percentage (%). CAD: Coronary artery Disease.  $P \leq 0.05$  (significant).

**Table 2(b). Genotype and allele frequencies of the T-786C polymorphism of the eNOS gene in CAD patients after classification according to BMI.**

|                 |                | CAD<br>(N=80)              |                      |                 | P 1<br>value | P2<br>value |
|-----------------|----------------|----------------------------|----------------------|-----------------|--------------|-------------|
|                 |                | Normal<br>weight<br>(n=40) | Overweight<br>(n=20) | Obese<br>(n=20) | 0.23         | 0.24        |
| <i>Genotype</i> | CC, n(%)       | 16(40%)                    | 9(45%)               | 10(50%)         |              |             |
|                 | TC, n(%)       | 13(32.5%)                  | 5(25%)               | 5(25%)          |              |             |
|                 | TT, n(%)       | 11(27.5%)                  | 6(30%)               | 5(25%)          |              |             |
| <i>Allele</i>   | C allele, n(%) | 45(56.25%)                 | 23(57.5%)            | 25(62.5%)       | 0.12         | 0.18        |
|                 | T allele, n(%) | 35(43.75%)                 | 17(42.5%)            | 15(37.5%)       |              |             |

Data are presented as number and percentage (%). CAD: Coronary artery Disease.  $P \leq 0.05$  (significant). P1=If comparing overweight patients with normal weight patients. P2= If comparing obese patients with normal weight patients.

**Table 3 (a).Genotype distribution and allele frequencies of 4b/a 27-bp repeats variant polymorphism of the eNOS gene in the study subjects**

| Genotype |                | Control<br>(n=40) | CAD<br>(n=80) | P value |
|----------|----------------|-------------------|---------------|---------|
| Genotype | bb, n(%)       | 14(35%)           | 36(45%)       | 0.15    |
|          | ab, n(%)       | 26(65%)           | 40(50%)       |         |
|          | aa, n(%)       | 0(0%)             | 4(5%)         |         |
| Allele   | b allele, n(%) | 54(67.5%)         | 112(70%)      | 0.12    |
|          |                |                   |               |         |
|          | a allele, n(%) | 26(32.5%)         | 48(30%)       |         |

Data are presented as mean± SE. n: number of cases, (%) = percentage of cases. CAD: Coronary artery Disease.  $p \leq 0.05$  (significant).

**Table 3(b). Genotype distribution and allele frequencies of eNOS 4b/a 27-bp repeats variant in CAD patients after classification according to BMI.**

|          |                | CAD<br>(N=80)           |                      |                 | P 1<br>value | P2<br>value |
|----------|----------------|-------------------------|----------------------|-----------------|--------------|-------------|
|          |                | Normal weight<br>(n=40) | Overweight<br>(n=20) | Obese<br>(n=20) | 0.28         | 0.43        |
| Genotype | bb, n(%)       | 17(42.5%)               | 9(45%)               | 10(50%)         |              |             |
|          | ab, n(%)       | 22(55%)                 | 9(45%)               | 9(45%)          |              |             |
|          | aa, n(%)       | 1(2.5%)                 | 2(10%)               | 1(5%)           |              |             |
| Allele   | a allele, n(%) | 23(28.75%)              | 13(32.5%)            | 11(27.5%)       | 0.18         | 0.23        |
|          | b allele, n(%) | 57(71.25%)              | 27(67.5%)            | 29(72.5%)       |              |             |

Data are presented as number and percentage (%). CAD: Coronary artery Disease.  $p \leq 0.05$  (significant). P1= If comparing overweight patients with normal weight patients. P2= If comparing obese patients with normal weight patients.



**Fig.A: 3% agarose gel stained with ethidium bromide showing bands of allele –specific PCR for T-786C polymorphism in e NOS gene, analyzed by electrophoresis.**

•**Lane (M):** Sibenzyme M15, 100bp DNA ladder.

•**Lane (1&2):** Show CC homozygote polymorphism of the T-786C e NOS gene at 250bp.

• **Lane (3 &4):** Show TC heterozygote polymorphism where T at 176bp &C at 250bp.

• **Lane (5 &6):** Show TT homozygote polymorphism at 176bp

•**Lane (7):** Negative control



**Fig.B: 3% agarose gel stained with ethedum bromide, showing bands of allele –specific PCR for intron 4 VNTR polymorphism in e NOS gene, analyzed by gel electrophoresis.**

•Lane (M): Sibenzyme M15, 100bp DNA ladder.

•Lane (1, 2, 4,6&7): Show bb homozygote polymorphism of the intron 4 VNTR in e NOS gene at 418 bp.

•Lane (3 &5): Show a b heterozygote polymorphism where a at 391bp & b at 418bp.

## Discussion:

Coronary artery disease (CAD) is multifactorial disorder with genotype and environmental interactions having an important role in its development (Weng et al., 2005).Therefore in addition to established risk factors such as obesity, hypertension, diabetes mellitus and sex, and genetic risk factors may have important roles in the pathogenesis of CAD (Kerkeni et al., 2006). Identification of these genetic risk factors is expected to enhance our understanding of the molecular basis for CAD. The epidemiologic studies performed during the last 50 years showed that there are many

genes responsible in the etiology of coronary atherosclerosis (**Lusis, 2000**). Over the last decade, a remarkable evidence has accumulated; offering that NO plays a pivotal role in CAD (**Syed et al., 2010**). The e NOS polymorphism may alter gene expression and may reduce the bioavailability of endothelial NO, thereby resulting in endothelial dysfunction (**Angeline et al., 2010**). Due to the importance of e NOS in the generation of NO, several epidemiological studies have investigated the relation between eNOS gene polymorphisms and CAD and have produced varied or contradictory results (**Thomas et al., 2002 and Vasilakou et al., 2008**).

Two polymorphisms in e NOS gene are reportedly associated with CAD: a 27-bp repeat [variable number of tandem repeat (VNTR)] polymorphism located in intron 4 of eNOS gene (eNOS 4b/a), and the T-786C single nucleotide polymorphism (SNP) in the 5'-flanking region (**Liu et al., 2005**).

It is well accepted that endothelial dysfunction occurs in response to cardiovascular risk factors and precedes the development of atherosclerosis (**Libby, 2001**). Mean while, it was indicated that point mutation of thymine (T) to cytosine(C) at nucleotide 786 (T-786C) in the 5'-flanking region of the eNOS gene could result in a significant reduction in the promoter activity by 50% (**Miyamoto et al., 2000**), suggesting that in many carriers of the mutant allele, the l-arginine/NO pathway does not function properly, leading to endothelial dysfunction (**Colombo et al., 2003**). Thus, it is possible that the T-786C mutation of the eNOS gene may make carriers susceptible to the development of endothelial dysfunction and in turn to CAD (**Leeson et al., 2002**). Data from other studies demonstrated that homozygosity (CC allele) for this polymorphism is associated with a deficit of eNOS expression in endothelial cells, as well as with a reduced NO-mediated vasomotor function (**Dosenko et al., 2006**), because the C allele creates a binding site for a replication protein A-1 that acts as a repressor of gene transcription (**Miyamoto et al., 2000**).

Consistent with those findings, **Nakayama et al. (1999)** suggested that the T-786C polymorphism of the eNOS gene contribute to CAD. The same authors recently reported that this mutation could decrease the concentration of serum nitrite/nitrate (NOx) significantly (**Nakayama et al., 2006**). **Rios et al. (2005)** indicated that a variant T-786C may be the most relevant eNOS polymorphism for the development of cardiovascular disease in the Brazilian population. These results agree with those described by **Tanus-Santos et al. (2001)** in the Caucasian population. A meta-analysis involving 22 studies that evaluated the association between the T-786C polymorphism and CAD showed that this genetic variant was associated with an increased risk of CAD (**Casas et al., 2006**). The T-786C mutation was also found to be significantly associated with CAD in Italian population (**Colombo et al 2003 and Rossi et al., 2003**), although, each study condition was slightly different.

In the current investigation a non-significant difference in the distribution of genotypes (cases: 43.75% CC, 28.75% CT, 27.5% TT) and control ( 27.5% CC, 37.5% CT, and 35% TT) was observed. Although The CAD patients showed remarkable proportion of mutant allele frequency of T-786C mutation, were the C allele frequency of T-786C polymorphism was higher in CAD than control individuals (58.12% vs. 46.25%,  $p=0.21$ ) it was not significant.

Comparable results were found by **Nassar et al. (2006)** in the Canadian population, where non significant increase in the frequency of the variant T-786C allele in the patients with premature CAD was recorded. Likewise, neither **Poirier et al. (1999)** in the French population, nor **Granath et al. (2001)** in the Australian Caucasian population found significant difference among CAD cases and controls with respect to eNOS T-786C polymorphism.

Further research regarding association of intron 4 VNTR polymorphism with CAD was considered. The intron 4 VNTR polymorphism have been demonstrated to bind nuclear proteins as an enhancer or repressor, resulting in promotion or suppression, respectively of the transcription efficiency (**Wang et al., 2002**). The intron 4 VNTR polymorphism is associated with altered plasma NO levels, influencing both NO and enzyme production and data from literature reported that it accounted for 25% of the variance of NO circulating levels (**Wang et al., 1997**). **Wang et al. (2002)** have demonstrated that the intron 4 VNTR polymorphism could also be potentially functional, since it not only binds to certain nuclear proteins, but also affects promoter efficiency. In the current study the genotype frequencies for intron 4 VNTR b/b , a/b and a/a were 45% , 50% and 5%, respectively for the CAD patients , and 35% , 65% and 0%, respectively for controls.

In the present study, the frequency of 4a allele was slightly higher but non significant in CAD patients compared to control individuals (30% vs. 32.5%) respectively. Consistent with these findings, (**Vasilakou et al., 2008**) did not find any association between the mutant alleles of eNOS 4b/a polymorphisms and the risk for premature CAD in the Greek population. Studies on German (**Sigusch et al, 2000**) or Japanese (**Elbaz et al, 2000**) patients also failed to observe such an association.

The molecular analysis of intron 4 VNTR polymorphism of demonstrated that this genetic variant was not associated with CAD in the studied population. In agree with current results, **Sigusch et al. (2002)** and **Hwang et al. (2002)** did not detect a link between this polymorphism and CAD in German and Taiwanese populations. In addition, **Granath et al. (2001)** found no evidence for an association between this polymorphism and CAD in the Australian Caucasian population.

In contrast, **Wang et al. (2002)** detected a significant association between intron 4 VNTR polymorphism and CAD. **Yoon et al. (2000)** also identified an association of this polymorphism with the risk of CAD. **Lee et al. (2001)** suggested that intron 4 VNTR polymorphism was significantly associated with the development of CAD in Korea. Other reports suggested potential associations of the intron 4 VNTR polymorphism with vascular disease **Fatini et al., (2004)** or endothelial dysfunction. **Li and Forstermann, (2000)** in Iranian population with CAD showed that eNOS4b/a polymorphisms were associated.

In contrast, the intron 4 VNTR polymorphism was found to be associated with coronary atherosclerosis in Australian (**Wang et al., 1996**), Japanese (**Ichihara et al., 1998**), and Afro-American patients (**Hooper et al., 1999**). Positive associations of (a) allele compared with (b) allele were reported in Caucasians with CAD (**Fowkes et al, 2000**). This discrepancy between different studies with eNOS gene polymorphism it could be the result of differences in ethnicity. Ethnic background is known to influence polymorphism frequencies and their effects on the disease. Additionally, These different results are likely a consequence of differences in exposure to risk factors, differences in sampling methods, different selection criteria adopted for patients and controls, in particular clinical presentation, extent of disease, age, race, geographical area, and concomitant environmental risk factors with in all can explain such discrepancies.

The present study extended also in order to determine the genotype distribution of the eNOS T-786C and intron 4 VNTR gene regions when CAD patients were classified according to their BMI into normal weight patients, overweight patients and obese patients groups, As far as we are aware it has not been previously reported that CAD is classified into subgroups according to BMI for the evaluation of polymorphisms in T-786C and intron 4 VNTR of the eNOS gene. When the control group and the whole CAD patient group (prior classification) were compared, no statistically significant difference

was found between the genotype frequencies of the T-786C promoter and intron 4 VNTR. The genotype distribution of the intron 4 "a a" allele was found to be 2.5%, 10%, and 5%, respectively in the normal weight, overweight, and obese groups. The distribution of this genotype in overweight and obese patients was found to be non-significantly differed when compared with the normal weight group. Distribution of the "bb" genotype in the normal weight, overweight, and obese groups was found to be 42.5%, 45% and 50%, respectively, however distribution of the "a b" genotype in the normal weight, overweight, and obese groups was found to be 55%, 45%, and 45%, respectively. The total proportion of individuals carrying the bb and ab genotype in the overweight and obese groups were statistically non-significant when compared the normal weight group. Accordingly no relationship was detected between eNOS T-786C gene polymorphism and different subgroups of CAD patients.

In conclusion, our results indicated that the eNOS T-786C and intron 4 VNTR polymorphisms are not independent predisposition risk factors for CAD in Egyptian population. However, this study is restricted by its sample size. Thus, larger studies are required to confirm the real association of these polymorphisms and CAD.

## References:

- (1) Abolhalaj, M.; Amoli, M. M. and Amiri, P. "eNOS Gene Variant in Patients with Coronary Artery Disease," Journal of Biomarkers, vol. 2013, Article ID 403783, 6 pages, 2013. doi:10.1155/2013/403783
- (2) Angeline, T.; Isabel, W. and Tsongalis, G. J. (2010): Endothelial nitric oxide gene polymorphisms, nitric oxide production and coronary artery disease risk in a South Indian population . Experimental and Molecular Pathol., 89 : 205–208
- (3) Ben Ali, M.; Messaoudi, S.; Ezzine, H. and Mahjoub, T. (2015): Contribution of eNOS Variants to the Genetic Susceptibility of Coronary Artery Disease in a Tunisian Population. Genetic Testing and Molecular Biomarkers., 19(4): 203-208. doi:10.1089/gtmb.2014.0261.

- (4) Casas, J. P.; Bautista, L. E.; Humphries, S. E. and Hingorani, A. D. (2004): Endothelial nitric oxide synthase genotype and ischemic heart disease: metaanalysis of 26 studies involving 23,028 subjects. *Circul.*, 109:1359–65.
- (5) Casas, J. P.; Cavalleri, G. L.; Bautista, L. E.; Smeeth, L.; Humphries, S. E.; Hingorani, D. A. (2006): Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. *Am. J. Epidemiol.*, 164:921–35.
- (6) Çelik, A.; Özçetin, M.; Ateş, Ö.; Altunkaş, F.; Karaman, K.; Akar, I.; İnce, I.; Yalçın, M.; Karayakalı, M.; Ceyhan, K. and Koç, F. (2015): Analyses of C-Reactive Protein, Endothelial Nitric Oxide Synthase and Interleukin-6 Gene Polymorphisms in Adolescents with a Family History of Premature Coronary Artery Disease: A Pilot Study. *Balkan Med J.*, 32:397-402.
- (7) Christus, T.; Shukkur, A. M.; Rashdan, I.; Koshy, T.; Alanbaei, M.; Zubaid, M.; Hayat, N. and Alsayegh, A. (2011) : Coronary Artery Disease in Patients Aged 35 or less – A Different Beast?. *Heart Views.*, 12(1): 7–11
- (8) Colombo, M.G.; Paradossi, U.; Andreassi, M. G.; Andreassi, M. G.; Botto, N.; Manfredi, S.; Masetti, S.; Biagini, A. and Clerico, A. ( 2003): Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease. *Clin. Chem.*, 49:389-395.
- (9) Davignon, J. and Ganz, P. (2004): Role of endothelial dysfunction in atherosclerosis. *Circul.*, 109:III27eIII32.
- (10) Domingos, L. S.; Rios, Lorenza, O.; D’Onofrio ; Joares, K.; Souza ; Am´alia, M. Queiroz ; Raduy-Marón, R.; Silva-Neto, N.; Heitor, G. C.; Santos-Filho, A. and Galvão-Castro, B. (2007): Smoking-dependent and haplotype-specific effects of endothelial nitric oxide synthase gene polymorphisms on angiographically assessed coronary artery disease in Caucasian- and African-Brazilians. *Atheroscl.*, 193 135–141
- (11) Elbaz, A.; Poirier, O.; Moulin, T.; Chedru, F.; Cambien, F. and Amarenco, P. (2000): Association between the Glu298Asp Polymorphism in the Endothelial Constitutive Nitric Oxide Synthase Gene and Brain Infarction. *Stroke*, 31: 1634-1639.
- (12) Fatini, C., Sofi, F.; Sticchi, E.; Gensini, F.; Gori, A. M.; Fedi, S.; et al. Influence of endothelial nitric oxide synthase gene polymorphisms (G894T, 4a4b, T-786C) and hyperhomocysteinemia on the predisposition to acute coronary syndromes. *Am Heart J* 2004;147:516.
- (13) Fowkes, F. G.; Lee, A. J.; Hau, C. M.; Cooke, A.; Connor, J. M. and Lowe, G. D. (2000): Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (eNOS) genes and

risks of peripheral arterial disease and coronary heart disease: Edinburgh Artery Study. Atherosclero., 150, 179-185.

(14)Granath, B.; Taylor, R. R.; vanBockxmeer, F. M. and Mamotte, C. D. (2001): Lack of evidence for association between endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in the Australian Caucasian population. J. Cardiovasc. Risk., 8:235-241.

(15)Hooper, W. C.; Lally, C.; Austin, H.; et al. The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African Americans. Chest 1999;116:880– 6

(16)Hwang, J. J.; Tsai, C. T.; Yeh, H. M., Chiang, F. T.; Hsu, K. L.; Tseng, C. D.; Liao, C. S.; Tseng, Y. Z.; Lai, L. P. (2002) Cardiol., 97, 67-7

(17)Ichihara, S.; Yamada, Y.; Fujimura, T.; Nakashima, N.; Yokota, M. (1998): Association of a polymorphism of the endothelial constitutive nitric oxide synthase gene with myocardial infarction in the Japanese population. Am. J. Cardiol.,81:83 – 6

(18)Kerkeni, M.; Addad, F.; Chauffert, M.; Myara, A.; Farhat, M. Miled, A.; Maaroufi, K. and Trivin, F.(2006): Hyperhomocysteinemia, endothelial nitric oxide synthase polymorphism, and risk of coronary artery disease. Clin. Chem., 52:53-58.

(19)Kim, I. J.: , Bae, J.; , Lim, S. W.; Cha, D. H.; Cho, H. J.; Kim, S. ; Yang, D. H.; Hwang, S. G.; Oh, D. and Kim, N. K. (2007): Influence of endothelial nitric oxide synthase gene polymorphisms (\_786TNC, 4a4b, 894GNT) in. Thromb. Res., 119, 579—585

(20)Kunns, T. A.; Ilveskoski, E.; Niskakangas, T.; Laippala, P.; Kajander, O. A.; Mikkelsen, J.; et al. Association of the endothelial nitric oxide synthase gene polymorphism with risk of coronary artery disease and myocardial infarction in middle-aged men. J Mol Med 2002;80:605–9.

(21)Lee, W. H.; Hwang, T. H.; Oh, G. T.; Kwon, S. U.; Choi, Y. H. and Park, J. E. (2001) Vasc. Med., 6(2),103-108.

(22)Leeson, C. P.; Hingorani, A. D.; Mullen, M. J.; Jeerooburkhan, N.; Kattenhorn, M.; Cole, T. J. Muller, D. P.; Lucas, A.; Humphries, S. E. and Deanfield, J. E. (2002): Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ. Res., 90:1153–1158.

(23)Li, H. and Forstermann, U. (2000): Nitric oxide in the pathogenesis of vascular disease. J. Pathol.,190:244.

- 530 (24)Libby, P. (2001): Current concepts of the pathogenesis of the acute coronary syndromes. *Circ.*,  
531 104:365–72.
- 532 (25)Liu, Y.; Kathryn, P. B.; Carl, D.; Langefeld; Stephanie, R.; Beck; Lynne, E.; Wagenknecht, S.  
533 S. R.; Donald, W.; Bowden and Barry, I. F. (2005): T-786C Polymorphism of the Endothelial  
534 Nitric Oxide Synthase Gene Is Associated with Albuminuria in the Diabetes Heart Study. *J.*  
535 *Am. Soc. Nephrol.*, 16: 1085-1090.
- 536 (26)Lusis, A. J. (2000): Atherosclerosis. *Nature*, 407:233– 41.
- 537 (27)Miyamoto, Y.; Saito, Y.; Nakayama, M.; Shimasaki, Y.; Yoshimura, T.; Yoshimura, M.;  
538 Harada, M.; Kajiyama, N.; Kishimoto, I.; Kuwahara, K.; Hino, J.; Ogawa, E.; Hamanaka, I.;  
539 Kamitani, S.; Takahashi, N.; Kawakami, R.; Kangawa, K.; Yasue, H. and Nakao, K. (2000):  
540 Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene  
541 containing a -786T→C mutation associated with coronary spastic angina. *Hum. Mol. Genet.*, 9:  
542 2629-2637.
- 543 (28)Nakayama, M.; Yasue, H.; Yoshimura, M.; Shimasaki, Y.; Kugiyama, K.; Ogawa, H.;  
544 Motoyama, T.; Saito, Y.; Ogawa, Y.; Miyamoto, Y. and Nakao, K. (1999): T-786—NC  
545 mutation in the 5V-flanking region of the endothelial nitric oxide synthase gene is associated  
546 with coronary spasm. *Circul.*, 99: 2864– 70.
- 547 (29)Nakayama, M.; Yoshimura, M.; Sakamoto, T.; Abe, K.; Yamamuro, M.; Shono, M.; Suzuki,  
548 S.; Nishijima, T.; Miyamoto, Y.; Saito, Y.; Nakao, K.; Yasue, H. and Ogawa, H.(2006): A-  
549 786T NC polymorphism in the endothelial nitric oxide synthase gene reduces serum  
550 nitrite/nitrate levels from the heart due to an intracoronary injection of acetylcholine.  
551 *Pharmacog. Genom.*,16:339–45.
- 552 (30)Nassar, B.; Rockwood, K.; Kirkland, S.; Ransom, T.; Darvesh, S. and Macpherson, K. (2006):  
553 Improved prediction of early-onset coronary artery disease using APOE 4, BCh-K, PPAR2  
554 Pro12 and ENOS T-786C in polygenic model. *Clin. Biochem.*, 39(2):109–14.
- 555 (31)Poirier, O.; Mao, C.; Mallet, C.; Nicaud, V.; Herrmann, S. M.; Evans, A.; Ruidavets, J. B.;  
556 Arveiler, D.; Luc, G.; Tiret, L.; Soubrier, F. and Cambien, F. (1999): Polymorphisms of the  
557 endothelial nitric oxide synthase gene – no consistent association with myocardial infarction in  
558 the ECTIM study. *Eur. J. Clin. Invest.*, 29:284-290.

- 559 (32) Qi, Z.; Shao-yong, S. U.; Shu-feng, Ch.; Biao, L. and Dongfeng, G. U. (2006): Association study  
560 of the endothelial nitric oxide synthase gene polymorphisms with essential hypertension in  
561 northern Han Chinese. *Chinese Med. J.*, 119(13):1065-1071
- 562 (33) Rios, D. L. S.; Callegari-Jacques, S. M. and Hutz, M. H. (2005): Endothelial nitric oxide  
563 synthase and fractalkine chemokine receptor polymorphisms on angiographically assessed  
564 coronary atherosclerosis. *Clin. Chim. Acta.*, 362:138–46.
- 565 (34) Rossi, G. P.; Cesari, M.; Zanchetta, M.; et al. The T-786C endothelial nitric oxide synthase  
566 genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA  
567 study. *J Am Coll Cardiol* 2003;41:930–7.
- 568 (35) Searles, C. D. (2006): Transcriptional and posttranscriptional regulation of endothelial nitric  
569 oxide synthase expression. *Am. J. Physiol. Cell Physiol.*, 291:C803eC816.
- 570 (36) Sigusch, H. H.; Surber, R.; Lehmann, M. H.; Surber, S.; Weber, J.; Henke, A.; Reinhardt, D.;  
571 Hoffmann, A. and Figulla, H. R. (2000): Lack of association between 27-bp repeat  
572 polymorphism in intron 4 of the endothelial nitric oxide synthase gene and the risk of coronary  
573 artery disease. *Scand. J. Clin. Lab.*, 60, 229-235.
- 574 (37) Sigusch, H.H.; Surber, R.; Lehmann, M. H.; Surber, S.; Weber, J.; Henke, A.; et al. (2002)  
575 *Scand J. Clin. Lab. Invest.*, 60, 22-27.
- 576 (38) SPSS 10 (1999): "SPSS for windows release 10.0.1 27 Oct 1999" Standard version, Copyright  
577 SPSS Inc.
- 578 (39) Stangl, K.; Cascorbi, I. and Laule, M. (2000): High CA repeat numbers in intron 13 of the  
579 endothelial nitric oxide synthase gene and increased risk of coronary artery disease.  
580 *Pharmacogenetics*, 10 : 133-40
- 581 (40) Syed, R.; Biyabani, M. U.; Prasad, S.; Deeba, F. and Jamil, K. (2010): Correlation and  
582 Identification of Variable Number of Tandem Repeats of eNOS Gene in Coronary Artery  
583 Disease (CAD). *Saudi J. Biol. Scienc.*, 10.1016
- 584 (41) Tanus-Santos, J. E.; Desai, M.; Flockhart, D. A. (2001): Effects of ethnicity on the distribution  
585 of clinically relevant endothelial nitric oxide variants. *Pharmacog.*, 11: 719–25.
- 586 (42) Termeer, M.; Bescos, J. O.; Breeuwer, M.; Vilanova, A.; Gerritsen, F. and Groller, M. E. (2007):  
587 Comprehensive Visualization of Coronary Artery Disease.
- 588 (43) Thomas, S.; Birkhead, A. and Wang, L. (2002): Effect of eNOS polymorphisms and coronary  
589 artery disease upon exhaled nitric oxide. *J. Mol., Med.* 80, 181–186.

- (44) Vasilakou, M.; Votteas, V.; Kasparian, C.; Pantazopoulos, N; Dedoussis, G.; Deltas, C.; Nastos, P.; Nikolakis, D. and Lamnissou, K. (2008): Lack of association between endothelial nitric oxide synthase gene polymorphisms and risk of premature coronary artery disease in the Greek population. *Acta. Cardiol.*, 63, 609–614.
- (45) Wang, J.; Dudley, D. and Wang, X. L. (2002): Haplotype-specific effects on endothelial NO synthase promoter efficiency: Modifiable by cigarette smoking. *Arterioscler. Thromb. Vasc. Biol.*, 22:1.
- (46) Wang, X. L. and Wang, J. (2000): Endothelial nitric oxide synthase gene sequence variations and vascular disease. *Mol. Genet. Metab.*, 70(4):241–51.
- (47) Wang, X. L.; Mahaney, M. C.; Sim, A. S.; Wang, J.; Blangero, J.; Almasy, L.; Badenhop, R. B. and Wilcken, D. E. L. (1997): Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. *Arterioscler. Thromb. Vasc. Biol.*, 17: 3147–3153.
- (48) Weng, L.; Kavaslar, N.; Ustaszewska, A.; Doelle, H.; Schackwitz, W.; Hébert, S.; Jonathan, C. C.; McPherson, R. and Pennacchio, L. A. (2005): Lack of MEF2A mutations in coronary artery disease. *J. Clin. Invest.*, 115:1016–1020.
- (49) World Health Organization. (2000): Obesity: preventing and managing the global epidemic. *WHO Technical Report Series*, 894:1–252.
- (50) Yang, Y.; Du, K.; Liu, Z. and Lu, X. (2014): Endothelial Nitric Oxide Synthase (eNOS) 4b/a-2 Gene Polymorphisms and Coronary Artery Disease :Evidence from a Meta-Analysis. *Int. J. Mol. Sci.*, 15: 7987-8003.
- (51) Yoon, S.; Shin, C.; Park, H.; Moon, J.; Kim, E.; Kim, H.; Min, J.; Jo, S. A. and Jo, I. (2005): Endothelial nitric oxide synthase gene is associated with vessel stenosis in Korean population. *Clin. Chim. Acta.*, 353 177–185